Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia
April 23, 2019 07:49 ET
|
Autolus Therapeutics plc
LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019
March 04, 2019 06:30 ET
|
Autolus Therapeutics plc
LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
June 15, 2018 01:30 ET
|
Erytech Pharma S.A.
LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic...
ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
May 14, 2018 16:30 ET
|
Erytech Pharma S.A.
Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3Selected triple-negative breast cancer as the next solid tumor...
ERYTECH annonce le dépôt de son Document de Référence 2017 et de son Form 20-F 2017
April 24, 2018 16:30 ET
|
Erytech Pharma S.A.
LYON, France, 24 avr. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), société biopharmaceutique de stade clinique développant à partir de sa plateforme propriétaire...
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
April 24, 2018 16:30 ET
|
Erytech Pharma S.A.
LYON, France, April 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of...
ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018
April 12, 2018 01:30 ET
|
Erytech Pharma S.A.
LYON, France, April 12, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...
Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China
January 09, 2017 06:10 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against The Allstate Corporation - ALL
December 23, 2016 16:50 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 23, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of The Allstate Corporation...